Upload
zeiss-group
View
1.495
Download
7
Tags:
Embed Size (px)
DESCRIPTION
Citation preview
Carl Zeiss Meditec AG
Company Presentation2013/2014
Pioneering Medical TechnologyCarl Zeiss Meditec AG
Carl Zeiss Meditec AG
With innovations for ophthalmology and microsurgery, the Medical Technology business group of ZEISS is contributing to progress in medicine. Our products and solutions aim to help physicians to improve patient outcomes and their patients’ quality of life.
Improving the quality of live
2
A world-leading medical technology company
Comprehensive systems to diagnose and treat eye diseases
Complete solutions for visualisation, microscopes for spinal, neuro/ENT, ophthalmic and dental procedures, IORT*
Ophthalmology Microsurgery
We drive progress in medicine, enabling doctors to achieve the best possible outcomes for their patients.
Results 2012/2013:
Revenue: € 906.4 mn; Growth: 5.2 %
EBIT: € 133.9 mn; EBIT margin: 14.8 %
Headquarters in Jena, Germany
More than 2,500 employees worldwide
Listed on the TecDAX
Around 65 % of the shares held by ZEISS
Carl Zeiss Meditec AG
At a GlanceCarl Zeiss Meditec AG
* IORT: Intraoperative Radiotherapy
3
Executive Board
At a GlanceCarl Zeiss Meditec AG
Dr. Ludwin Monz (President & CEO) Dr. Christian Müller (CFO) Thomas Simmerer (CSO)
Carl Zeiss Meditec AG
From left to right: Dr. Ludwin Monz, Thomas Simmerer, Dr. Christian Müller
4
Broad Product PortfolioWe Offer Our Customers an Extensive Portfolio
Carl Zeiss Meditec AG
Private practitioners
OphthalmicSystemsSales FY 12/13:€ 391 mn
Clinics
Surgical Oncology
Ambulatorysurgerycenters
Hospitals
Cataract Surgery
Visualisation & Microsurgery
Glaucoma & RetinaDiagnosis & Therapy
Corneal Refractive Surgery
Customers SBUSegments Products
MicrosurgerySales FY 12/13:€ 394.2 mn
SurgicalOphthalmologySales FY 12/13:€ 121.3 mn
5
Carl Zeiss Meditec AG
Americas APACEMEA
36.1% 33.9% 29.9%
Growth & Revenue Split by RegionsFY 2011/12 FY 2012/13
Results at a Glance (FY 12/13)All Regions and Strategic Business Units Contributed To Growth
Growth & Revenue Split by SBUs* FY 2011/12 FY 2012/13
Microsurgery OphthalmicSystems
Surgical Ophthalmology
+ 12.6 %+ 4.0 %+ 4.2 %
13.4%43.5% 43.1%
* SBU: Strategic Business Unit
+ 7.8 % + 5.9 % + 1.4 %
6
Financials at a Glance (FY 12/13)Carl Zeiss Meditec AG
Revenue
€ 906.4 mnIncrease compared to FY 11/12: 5.2 %
EBIT
€ 133.9 mnResult
€ 93.5 mn*
EBIT-Margin
14.8 %
Carl Zeiss Meditec AG 7
* Consolidated net income after non-controlling interests
Success StoryNumbers Defining Growth
70 % Carl Zeiss Meditec holds 70 percent market share of surgical microscopes for neurosurgery
Carl Zeiss Meditec AG
4 millionTo date, more than 4 million surgeries around the world have been performed with OPMI® Pentero®
and OPMI® PENTERO® 900
8
Success StoryNumbers Defining Growth
Carl Zeiss Meditec AG
50 %Today, more than half of all Optical Coherence Tomography Systems (OCT) in ophthalmological practicesare ZEISS OCTs
75 %Around 75 percent of all cataract patients come into contact with a product from ZEISS during their treatment
9
10.7 %In FY 12/13, Carl Zeiss Meditec AG has invested 10.7 percent of its revenue in Research & Development
Success StoryNumbers Defining Technology Leadership
1.8 millimetersAn incision of 1.8 millimeters is all that is needed to insert a ZEISS intraocular lens into a patient’s eye
Carl Zeiss Meditec AG
Lens diameter(optics)6 mm
Incision length1.8 mm
10
Dividend | Total Dividend distributedin € | in € million
Additional special dividendRegular dividend
Dividend reflects Company‘s successInvestment in the Future of Health Care
Carl Zeiss Meditec AG 11
* Propose to the Annual General Meeting
0.18 0.18 0.22 0.30 0.40 0.45*
0.33
14.6 14.6
44.7
24.4
32.336.6
07/08 09/10 11/1208/09 10/11 12/13
0.45*
Recognizing OpportunitiesMeeting Today‘s Challenges
Global Mega Trends
Carl Zeiss Meditec AG 12
Global marketDemographic Change
Technological Change
Carl Zeiss Meditec AG
Demographic ChangeThe Proportion of Older People is Growing
13
Carl Zeiss Meditec AG
Demographic ChangeComprehensive Solutions for TypicalAge-related Diseases
„The proportion ofolder people in theoverall population isgrowing in many partsof the world. We offercomprehensivesolutions for thediagnosis andtreatment of typicalage-related diseases.“
Dr. Ludwin Monz
President & CEO
14
Demographic ChangeInnovations for Age-related Diseases
15Carl Zeiss Meditec AG
CALLISTO eye ® assists cataract surgeons with the precision alignment of IOLs
40 %Lens clouded by cataract
Vision with cataractNormal vision
of the population will develop cataracts
15
Demographic change
Technological change
Technological ChangeThe Medical Sector is Rapidly Changing
Global market
Carl Zeiss Meditec AG 16
Carl Zeiss Meditec AG
Technological ChangeExpanding the Possibilities of Medicine
„The entire medicalsector is rapidlybecoming digitized. And we, as one of thefront runners, areplaying an activerole.“
Dr. Christian Müller
Member of theManagement Board
17
100 Years of Leadership in Medical TechnologyGold Standard Products Defining the Market
OPMI® HFA™
PerimeterOCT 1 IOLMaster®
VisuMax ®
FemtosecondSystem
Slit lamp
Pace-setting innovation for more than 100 years
Carl Zeiss Meditec AG 18
Carl Zeiss Meditec AG
Patients have high expectations of clinical outcomes
Technological LeadershipPioneering Refractive Laser Technology
Minimally-invasive refractive laser surgery with ReLEx® smile
ReLEx® smile: Minimally invasive treatment methods set new standards in refractive surgery
19
Technological LeadershipThe Next Generation of Surgical Microscopes
Brilliant visualization in Neurosurgerywith OPMI® PENTERO® 900
Carl Zeiss Meditec AG 20
Technological LeadershipDisruptive Innovation in Breast CancerTreatment
Innovative breast cancer treatmentwith INTRABEAM®
Carl Zeiss Meditec AG 21
Global market
Global MarketThe World is Converging
Demographic change
Technological change
Carl Zeiss Meditec AG 22
Global MarketWe Are Well Aware of Our Customers‘ Demands
Carl Zeiss Meditec AG
„Through our global network we are wellaware of ourcustomers‘ demands. We use thisknowledge to definestandards which wethen put into practicethrough international training courses.“
Thomas Simmerer
Member of theManagement Board
23
Spain:Madrid
US:Dublin
Japan:Tokyo
Germany:JenaBerlinOberkochenMunich
France:Marly-le-RoiLa RochelleParis
Company sites of the Carl Zeiss Meditec Group Production, sales, service, R&D
Sales and Service sites of the Carl Zeiss Meditec Group
Sales and Service sites of the ZEISS Group
Global PresenceMore Than 30 Sites Worldwide in Every Major Market
Carl Zeiss Meditec AG 24
Global KnowledgeSharing knowledge through worldwide training with the ZEISS ACADEMY
Employee training in Jena
Training workshop in Hong Kong with customers
Carl Zeiss Meditec AG 25
ChinaSouth
East Asia
India
Brazil
Mexico
R&D Centers in rapidly developing economies
Global InnovationResearch and Development in RapidlyDeveloping Economies
Carl Zeiss Meditec AG 26
Our AspirationEvery Patient in Our Segment is Treated With One of our Products
Our Aspiration
Carl Zeiss Meditec AG
“We want to make our products and services
accessible and relevant to doctors’ needs
all over the world –so that in our segments
every patient can be treated with one of our products.”
27
Corporate Social ResponsibilityEyesight is Not „Normal“ For Everyone
Source: D. Pascolini, S.P. Mariotti, “Global estimates of visual impairment”, Br. J. Ophthalmol. 96, 614 - 618 (2012).
285 million people are visually impaired
1-2 million people go blind per year
39 million people are blind
Carl Zeiss Meditec AG 28
Corporate Social ResponsibilitySupporting Doctors to Bring Highest Level ofClinical Care to Their Patients All Over The World
Support for the Fellowship program of the International Council of Ophthalmology(ICO): In November 2013, ZEISS invited five of the fellows
Carl Zeiss Meditec AG 29
Goal of VISION 2020:
“By 2020, the primary causes of preventable blindness will be eliminated to ensure that everyone around the world receives a right to sight.”
Initiated by the World Health Organization (WHO) and the International Agency for the Prevention of Blindness (IAPB) in 1999
The ZEISS Medical Technology Business Group supports the VISION 2020 initiative together with other NGO’s, professional associations, ophthalmic institutes and companies
Corporate Social ResponsibilityThe VISION 2020 Initiative Will Spare Around 100 Million People From Blindness
Carl Zeiss Meditec AG 30
Medical Technology Business GroupFirmly anchored in the ZEISS Group
Medical and Research Solutions Industrial Solutions Lifestyle
Products
Busi
ness
Gro
ups
Medical Technology Microscopy Semiconductor
Manuf. Tech.Industrial Metrology
Camera Lenses, Sports Optics, Planetariums
Vision Care
Carl Zeiss AG
Mar
kets
Rev
enue
FY12
/13
€ 1.032 m* € 629 m € 934 m € 528 m € 195 m € 841 m
Vision Care
Carl Zeiss Meditec AG
* The values deviate from the published figures of Carl Zeiss Meditec Group as a result of different consolidation models.
31